{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T14:36:52Z","timestamp":1776695812290,"version":"3.51.2"},"reference-count":37,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Although metastatic cutaneous melanoma is associated with an unfavorable prognosis, innovative therapies including immunomodulating agents and targeted therapies have shown survival benefits in clinical trials. We assessed the impact of the introduction of innovative drugs into clinical practice on the survival of patients with metastatic cutaneous melanoma during the period 2004\u20132017, in Belgium. The evolution of associated expenses was also analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a retrospective population\u2010based study using data from the national Belgian Cancer Registry, compulsory health insurance, and administrative survival data. The immunomodulating drugs were ipilimumab, nivolumab and pembrolizumab, while targeted therapies included vemurafenib, dabrafenib and trametinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We did not identify a trend for improvement over time. Median survival (years) was 1.5 (95% CI: 1.1\u20131.8) in 2004\u20132008, 1.1 (95% CI: 0.8\u20131.5) in 2009\u20132013, and 1.6 (95% CI: 1.3\u20132.4) in 2014\u20132017, respectively. In contrast, survival improved in those with unknown primary tumor localization. In this group, median survival time was 2.0 (95% CI: 1.4\u20132.9) in the most recent period, while it was 1.1 (95% CI: 0.7\u20131.3) in 2009\u20132013, and 0.9 (95% CI: 0.6\u20131.2) in 2004\u20132008. The uptake of innovative drugs remained modest, with no drug being used by more than 30% of patients. Yearly expenditure was almost non\u2010existent, and gradually increased, reaching several million euros in 2014\u20132017.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Patients with metastatic cutaneous melanoma who were diagnosed between 2004 and 2017 showed no apparent improvement in survival. In contrast, increased survival was observed in the subgroup of patients with unknown primary tumor localization.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ijd.17046","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T04:45:15Z","timestamp":1706762715000},"page":"947-955","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Survival of patients with unfavorable prognosis cutaneous melanoma with increased use of immunotherapy agents: a\u00a0population\u2010based study in Belgium"],"prefix":"10.1111","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7112-2070","authenticated-orcid":false,"given":"Diego","family":"Castanares\u2010Zapatero","sequence":"first","affiliation":[{"name":"Belgian Health Care Knowledge Centre (KCE)  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leen","family":"Verleye","sequence":"additional","affiliation":[{"name":"Belgian Health Care Knowledge Centre (KCE)  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Devos","sequence":"additional","affiliation":[{"name":"Belgian Health Care Knowledge Centre (KCE)  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Thiry","sequence":"additional","affiliation":[{"name":"Belgian Health Care Knowledge Centre (KCE)  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert","family":"Silversmit","sequence":"additional","affiliation":[{"name":"Belgian Cancer Registry (BCR)  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Van Damme","sequence":"additional","affiliation":[{"name":"Belgian Cancer Registry (BCR)  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"De Gendt","sequence":"additional","affiliation":[{"name":"Belgian Cancer Registry (BCR)  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Hulstaert","sequence":"additional","affiliation":[{"name":"Belgian Health Care Knowledge Centre (KCE)  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattias","family":"Neyt","sequence":"additional","affiliation":[{"name":"Belgian Health Care Knowledge Centre (KCE)  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"e_1_2_6_2_1","volume-title":"Cancer fact sheets [Web page]","author":"Belgian Cancer registry (BCR)","year":"2019"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb2019760"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S99021"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-10-23"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5269062"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12802"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000299"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414428"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4059"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz411"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13257"},{"key":"e_1_2_6_16_1","first-page":"CD011123","article-title":"Systemic treatments for metastatic cutaneous melanoma","volume":"2","author":"Pasquali S","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12848"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2034861"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2014.10.009"},{"key":"e_1_2_6_20_1","unstructured":"World health organization (WHO).Statistical Classification of Diseases and Related Health Problems from the World Health Organization [Web page].2019. Available from:https:\/\/www.who.int\/standards\/classifications\/classification\u2010of\u2010diseases"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_22_1","first-page":"101","article-title":"The relative survival rate: a statistical methodology","volume":"6","author":"Ederer FAL","year":"1961","journal-title":"Natl Cancer Inst Monogr"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.07.002"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092591"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32229"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020168"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16419"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31828eed39"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.07.038"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.11.028"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.12.002"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15642"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15308"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0152"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2016.1184155"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-015-0757-y"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15957"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.57598\/R343C"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.17046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T06:08:18Z","timestamp":1744006098000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.17046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1111\/ijd.17046"],"URL":"https:\/\/doi.org\/10.1111\/ijd.17046","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]},"assertion":[{"value":"2023-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}